C

Cooper University Health Care | Internal Medicine Department

Research site

(Unclaimed)

Location

1 Cooper Plaza, Camden, New Jersey, United States of America

Site insights

Top conditions

Top treatments

Heparin

NSAID

Fentanyl Citrate

Budigalimab

Ketamine Hydrochloride

Lidocaine

ABBV-382

Bevacizumab

Acetaminophen

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 23 total trials

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Active, not recruiting

Human Immuno-deficiency Virus (HIV) Disease

Drug: Placebo for Budigalimab

Drug: Budigalimab

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (ATTACC-CAP)

This is an international, open-label, stratified randomized controlled trial with Bayesian adaptive stopping rules to compare the effects of therapeu...

Enrolling

Community-acquired Pneumonia

Drug: Heparin

Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms

Real-world clinical practice multicenter study to determine the clinical implications of employing PCR/NGS technology to identify and treat potential...

Enrolling

Interstitial Cystitis

Bladder Pain Syndrome

Diagnostic Test: Polymerase Chain Reaction and Next-Generation DNA Sequencing

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects (FLAMINGO-01)

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive an...

Enrolling

Breast Cancer

Biological: Placebo

Biological: GLSI-100